|
|
|
FSH-Elisa
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
FSH-ELISA |
OD
units Polychromatic model |
|
|
Calibrator |
0
mIU/ml 1
mIU/ml 5
mIU/ml 15
mIU/ml 50
mIU/ml 150
mIU/ml |
0.011 0.085 0.374 1.222 2.908 4.575 |
XII.
PERFORMANCE
AND
LIMITATIONS
A.
Detection Limit
Twenty
zero calibrators were assayed along with a set of other calibrators. The
detection limit, defined as the apparent concentration two standard deviations
above the average OD at zero binding, was 0.15 mIU/ml.
B.
Specificity
Cross-reactive
hormones (FSH, TSH & hCG) were added to the zero calibrator and to a high
value calibrator (30 mIU/ml). The
apparent FSH response was measured.
|
added
Hormone |
FSH
CAL 0 mIU/ml |
FSH
CAL 30 mIU/ml mIU/ml |
|
- |
0.0 |
30.3 |
|
LH
250 mIU/ml |
0.0 |
26.2 |
|
TSH
250 µIU/ml |
0.07 |
28.5 |
|
hCG
86 IU/ml |
0.35 |
25.0 |
C.
Precision
|
INTRA
ASSAY |
INTER
ASSAY |
||||||
|
Serum |
N |
<
>
± SD (mIU/ml) |
CV (%) |
Serum |
N |
<
>
± SD (mIU/ml) |
CV (%) |
|
A B C |
23 23 22 |
0.8
± 0.04 4.0
± 0.3 53.0
± 3.5 |
5.6 6.8 6.7 |
A B |
20 20 |
7.7
± 0.3 17.9
± 0.9 |
3.6 3.9 |
SD
: Standard Deviation; CV: Coefficient of variation
D.
Accuracy
RECOVERY
TEST
|
Sample |
Added
FSH (mIU/ml) |
Recovered
FSH (mIU/ml) |
Recovery (%) |
|
Serum
|
57.3
39.2
30.2
24.8
|
59.6
39.6
31.7
24 |
104
101
105
97 |
|
DILUTION
TEST |
|||
|
Sample |
Dilution |
Theoretical
Concent. (mIU/ml) |
Measured
Concent. (mIU/ml) |
|
FSH-1
FSH-2 |
1/1 1/2 1/5 1/10 1/20 1/50 1/100 1/1 1/2 1/5 1/10 1/20 |
-
34.8
13.9
7.0
3.5
1.4
0.7
-
33.0
13.2
6.6
3.3 |
69.6
27.2
13.0
7.2
3.8
1.3
0.9
66.0
29.2
13.2
7.3
3.5 |
Samples
were diluted with zero calibrator.
E.
Time delay between last calibrator and sample dispensing
As
shown hereafter, assay results remain accurate even when a sample is dispensed
40 minutes after the calibrators have been added to the coated wells.
|
TIME
DELAY |
|||||
|
|
T0 |
10
min |
20
min |
30
min |
40
min |
|
1052 1540 1338 |
3.9 21.9 100.6 |
3.9 22.2 105.0 |
3.5 22.4 102.5 |
3.7 22.0 94.4 |
3.4 19.4 99.5 |
F. Hook effect
A
sample spiked with FSH up to 2000 mIU/ml gives higher OD’s than the last
calibrator point.
XIII.
INTERNAL QUALITY
CONTROL
§
If the results obtained for Control 1 and/or Control 2 are not within the
range specified on the vial label, the results cannot be used unless a
satisfactory explanation for the discrepancy has been given.
§
If desirable, each laboratory can make its own pools of control samples,
which should be kept frozen in aliquots. Controls
that contain azide will interfere with the enzymatic reaction and cannot be
used.
§
Acceptance criteria for the difference between the duplicate results of
the samples should rely on Good Laboratory Practises
§
It is recommended that Controls be routinely assayed as unknown samples
to measure assay variability. The
performance of the assay should be monitored with quality control charts of the
controls.
§
It is good practise to check visually the curve fit selected by the
computer.
These
values are given only for guidance; each laboratory should establish its own
normal range of values.
The
range is expressed as 2.5% to 97.5% percentiles.
|
Identification |
Number
of subjects |
Mean (mIU/ml) |
Range (mIU/ml) |
|
Children .
Newborn to onset of puberty -
Girls
- Boys .
Puberty -
Girls
- Boys Adult
males Women .
Ovulatory cycles -
Follicular phase (day –10 to -4) -
Ovulatory peak (day 0) -
Luteal phase (day +4 to +10) .
Postmenopausal |
21 15 6 6 85 18 19 19 60 |
2.6 0.9 4.1 3.4 4.8 5.8 11.9 3.3 45.4 |
0.6
– 6.7 0.4
– 1.8 2.3
– 5.2 1.3
– 7.6 0.8
– 16.6
3.4 – 7.7 5.6
– 18.8 1.4
– 6.1 4.8
– 78.4 |
XV.
PRECAUTIONS
AND
WARNINGS
Safety
For
in vitro diagnostic use only.
The
human blood components included in this kit have been tested by European
approved and/or FDA approved methods and found negative for HBsAg, anti-HCV,
anti-HIV-1 and 2. No known method
can offer complete assurance that human blood derivatives will not transmit
hepatitis, AIDS or other infections. Therefore,
handling of reagents, serum or plasma specimens should be in accordance with
local safety procedures.
All
animal products and derivatives have been collected from healthy animals. Bovine
components originate from countries where BSE has not been reported.
Nevertheless, components containing animal substances should be treated as
potentially infectious.
Avoid
any skin contact with all reagents, Stop
Solution contains H2SO4, the chromogen contains TMB in
Dimethylformamide, Substrate buffer contains H2O2.
In case of contact, wash thoroughly with water.
Do
not smoke, drink, eat or apply cosmetics in the working area.
Do not pipette by mouth. Use
protective clothing and disposable gloves.
XVI.
BIBLIOGRAPHY
1.
CHAPPEL S.C., ULLOA-AGUIRRE A., COUTIFARIS C.
(1983)
Biosynthesis
and secretion of follicle-stimulating hormone.
Endocrinol.
Rev. 4:179.
2.
CROWLEY W.F., FOLICORI M., SPRAIT D.I., SANTORO N.F. (1985)
They
physiology of gonadotrophin-releasing hormone (GnRH) secretion in men and women.
Recent
Prog. Horm. Res; 41:473.
3.
WIDE L. (1987)
Evidence
for diverse structural variations of the forms of human FSH within and between
pituitaries.
Acta Endocrinol. 115:7.
4.
CLARKE J.J.,
CUMMINS J.T. (1987)
Pulsatility
of reproductive hormones: physiological basis and clinical implications.
Baillière's
Clin. Endocrinol. Metab.,
1:1
5.
FILICORI M.,
SANTORO N., MERRIAN G.R., CROWLEY W.F. Jr., (1986)
Characterization
of the physiological pattern of episodic gonadotropin secretion throughout the
human menstrual cycle.
J.
Clin. Endocrinol. Metab., 62:1136
6.
MAIS V., CETEL N.S., MUSE K.N., QUIGLEY M.E., REID R.L., YEN S.S.C.
(1987)
Hormonal
dynamics during luteal-follicular transition.
J.
Clin. Endocrinol. Metab., 64:1109
7.
LOUMAYE E., VANKRIEKEN L., DEPREESTER S., PSALTI I., de COOMAN S., THOMAS
K. (1989)
Hormonal
changes induced by short-term administration of a gonadotropin-releasing hormone
agonist during ovarian hyperstimulation for in vitro fertilization and their
consequences for embryo development.
Fertil.
and Steril., 51:105
8.
VERMES I., BONTE H.A., SLUIS VEER G., SCHOEMAKER J. (1991)
Interpretations
of five monoclonal immunoassays of Lutropin and Follitropin: effects of
normalization with WHO standard.
Clin.
Chem., 37:415
9.
MASSA G., de ZECHER F., VANDERSCHUREN-LODEWYK K. (1992)
Serum
levels of immunoreactive Inhibine, FSH and LH in human infants at Preterm and
Term Birth.
Biol.
of the Neonat., 61:150
10.
DE HERTOGH R., VANKRIEKEN L., THOMAS K. de GASPARO M. (1992)
Circhoral
fluctuations of serum total renin, inhibin and related hormones around the
mid-cycle in normal human females.
Hum.
Reprod., 7:337
XVII.
SUMMARY OF THE PROTOCOL
|
|
CALIBRATORS (µl) |
SAMPLE(S) CONTROLS (µl) |
|
Calibrators
(0-5) Samples,
Controls Anti-FSH-HRP
conjugate |
50 - 50 |
- 50 50 |
|
Incubate
for 30 min at room temperature with continuous shaking at 700 rpm. Aspirate
the contents of each well. Wash
3 times with 400 µl of Wash Solution and aspirate. |
||
|
Revelation
Solution |
200 |
200 |
|
Incubate
for 15 min at room temperature with continuous shaking at 700 rpm. |
||
|
Stop
Solution |
50 |
50 |
|
Read
on a microtiterplate reader and record the absorbance of each well at
450 nm (versus 630 or 650 nm) and 490 nm (versus 630 or 650 nm) |
||
|